Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Pralay, Mukhopadhyay"'
Autor:
Khader Shameer, Youyi Zhang, Dan Jackson, Kirsty Rhodes, Imran Khan A. Neelufer, Sreenath Nampally, Andrzej Prokop, Emmette Hutchison, Jiabu Ye, Vladislav A. Malkov, Feng Liu, Antony Sabin, Jim Weatherall, Cristina Duran, Renee Bailey Iacona, Faisal M. Khan, Pralay Mukhopadhyay
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Early endpoints, such as progression-free survival (PFS), are increasingly used as surrogates for overall survival (OS) to accelerate approval of novel oncology agents. Compiling trial-level data from randomized controlled trials (RCTs) could help to
Externí odkaz:
https://doaj.org/article/84b729da2ab44fd6bcfdfede4b9ff618
Autor:
Mario Ouwens, PhD, Annie Darilay, PhD, Yiduo Zhang, PhD, Pralay Mukhopadhyay, PhD, Helen Mann, MSc, James Ryan, MSc, Phillip A. Dennis, MD
Publikováno v:
Current Therapeutic Research, Vol 95, Iss , Pp 100640- (2021)
ABSTRACT: Background: Historically, the standard of care for patients with unresectable, Stage III non–small cell lung cancer had been concurrent chemoradiotherapy. However, outcomes had been poor, with approximately 15% to 32% of patients alive at
Externí odkaz:
https://doaj.org/article/a4a5cc50eaa1447b9143369b9f810389
Autor:
Faisal Khan, Shameer Khader, Youyi Zhang, Daniel Jackson, Kirsty Rhodes, Imran Khan Anwer Neelufer, Sreenath Nampally, Andrzej Prokop, Emmette Hutchison, Jiabu Ye, Feng Liu, Antony Sabin, James Weatherall, Cristina Duran, Renee Iacona, Pralay Mukhopadhyay
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/1db2c31bb5ed40ba9d561bb18d4f0cba
Autor:
Magdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, Xiaoping Jin, Yong Ben, Joyce Antal, Ashok K Gupta, Marlon C Rebelatto, J Andrew Williams, Jill Walker
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231936 (2020)
BackgroundStudies have indicated that programmed death ligand 1 (PD-L1) expression may have utility as a predictive biomarker in patients with advanced/metastatic urothelial carcinoma (UC). Different immunohistochemical (IHC) assays are in developmen
Externí odkaz:
https://doaj.org/article/796cbdd538a5493794df55e8aa3a8465
Autor:
Jiabu Ye, Binbing Yu, Helen Mann, Antony Sabin, Zsolt Szijgyarto, David Wright, Pralay Mukhopadhyay, Cristian Massacesi, Serban Ghiorghiu, Renee Iacona
Publikováno v:
Journal of Data Science. :1-18
We assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on the statistical analysis of time-to-event outcomes in late-phase oncology trials. Using a simulated case study that mimics a Phase III ongoing trial during the pandemic, we
Publikováno v:
JAMA Oncology. 9:572
Publikováno v:
Journal of Biopharmaceutical Statistics. 30:1130-1146
The novel mechanism of action of immunotherapy agents, in treatment of various types of cancer, poses unique challenges during the designing of clinical trials. It is important to account for possibility of a delayed treatment effect and adjust sampl
Publikováno v:
Clinical Pharmacology and Therapeutics
PD-1/PD-L1 immune checkpoint blockade (ICB) has improved overall survival (OS) in solid tumor trials; however, parallel improvements in Response Evaluation Criteria in Solid Tumors (RECIST)-based surrogate end points, progression-free survival (PFS),
Autor:
Alexandra Drakaki, Michael S. Gordon, Shaad Essa Abdullah, Wenmei Huang, Michael Ong, Jingsong Zhang, Natasha Angra, Pralay Mukhopadhyay, Xiang Guo, Arnold Degboe, Srikala S. Sridhar, Ashok K. Gupta, Alexander I. Spira, Hendrick Tobias Arkenau, Terence W. Friedlander, Peter H. O'Donnell, Lorin Roskos
Publikováno v:
Cancer. 126:432-443
BACKGROUND: Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health‐related quality of life (HRQOL). Here, patient‐reported ou
Publikováno v:
AMIA Annu Symp Proc
Combination therapies are an emerging drug development strategy in cancer, particularly in the immunooncology (IO) space. Many combination studies do not meet their safety objectives due to serious adverse events (SAEs). Prediction of SAEs based on e